Strategies to Target Tumor Immunosuppression
Georgia Koutsoumpli , Oana Draghiciu , Hans W Nijman , Cesar Oyarce
Cancer Immunology: Bench to Bedside Immunotherapy of Cancers 61 -83
2021
Ovarian cancer
Marian JE Mourits , Florine A Eggink , Mathilde Jalving , Marco de Bruyn
Bohn Stafleu van Loghum 591 -604
2019
Development and preclinical evaluation of an alphavirus therapeutic cancer vaccine against cervical cancer
Stephanie van de Wall , Annemarie Boerma , Joke Regts , Baukje-Nynke Hoogeboom
Design and delivery strategies of alphavirus replicon-based cervical cancer vaccines 23 -23
2018
The prognostic benefit of CD27+ tumor-infiltrating lymphocytes in cervical cancer: implications for treatment regimen
Stephanie van de Wall , Oana Draghiciu , Marco de Bruijn , Annemarie Boerma
Design and delivery strategies of alphavirus replicon-based cervical cancer vaccines 131 -131
2018
An immunotherapeutic design approach an alphavirus-based immunotherapeutic vaccine, PD-1 blockade and sunitinib
Stephanie van de Wall , Amrita Singh , Baukje-Nynke Hoogeboom , Annemarie Boerma
Design and delivery strategies of alphavirus replicon-based cervical cancer vaccines 95 -95
2018
Systemic immunological changes during first line chemotherapy in patients with high-grade serous ovarian cancer
Fenne L Komdeur , Florine A Eggink , Ninke Leffers , Hagma H Workel
Cancer Research 77 ( 13_Supplement) 1687 -1687
2017
Tumor stroma in serous ovarian cancer; inter and intra patient heterogeneity and impact on survival
Sara Corvigno , Bea Wisman , Ate GJ Van der Zee , Hans W Nijman
Cancer Research 75 ( 15_Supplement) 1537 -1537
2015
Radical vaginal trachelectomy in the Netherlands
Jonas van de Lande , Maaike APC van Ham , Petronella AJ van den Akker , Hans W Nijman
A step-by-step approach to early stage cervical cancer treatment 93 -93
2013
PML nuclear bodies are positively associated with HLA class I expression in ovarian cancer
Yuxuan Liu , Maartje CA Wouters , Ninke Leffers , Hans W Nijman
Novel insights in the pathogenesis of Hodgkin lymphoma 153 -153
2013
Age-Related Differences in Patient Preferences for Adjuvant Chemotherapy for High-Risk Endometrial Cancer
Famke C Wakkerman , Cathalijne CB Post , Jan-Willem M Mens , Ina Jurgenliemk-Schulz
Pre-existinginflammatoryimmune microenvironmentpredictstheclinical responseofvulvarhigh-grade squamousintraepitheliallesionsto therapeuticHPV16vaccination
Ziena Abdulrahman , Noel de Miranda , Edith MG van Esch , Peggy J de Vos van Steenwijk
kin-6 are opposite markers for survival and in-filtration with mature myeloid cells in ovarian cancer
Maartje CA Wouters , Eveline M Dijkgraaf , Marieke L Kuijjer , Ekaterina S Jordanova
and clear cell endometrial cancer Claudin-6 is a target for therapy in serous ovar-ian cancer and serous and clear cell endome-trial cancer
Maartje CA Wouters , Stefan Wöll , Marco de Bruyn , Toos Daemen
Gynecologic Oncology Reports
Koen De Decker , Henk G ter Brugge , Joost Bart , Roy FPM Kruitwagen
Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte
Sjoerd Van Der Burg Svejgaard , Hans W Nijman , Cornelis JM Melief , Mogens H Claesson
POLE proofreading mutations elicit an anti-tumor immune response in endometrial cancer
THBM Smit , Hans W Nijman , Tjalling Bosse , David N Church
Introduction to the thesis
Marco de Bruyn , Valerie R Wiersma , Maartje CA Wouters , Douwe F Samplonius
Thesis summary and discussion
Marco de Bruyn , Valerie R Wiersma , Maartje CA Wouters , Douwe F Samplonius
THE VALUE OF TUMOR-INFILTRATING T-LYMPHOCYTES AS PROGNOSTIC BIOMARKERS FOR LOCALLY ADVANCED CERVICAL CANCER WITH RADIO (CHEMO) THERAPY
Oana Draghiciu , Stephanie van de Wall , Annemarie Boerma , Aniek Boers
An overview of innovative techniques to improve cervical cancer screening.
Harry Hollema , Albert J. H. Suurmeijer , G. Bea A. Wisman , Esther R. Nijhuis
Cellular Oncology 28 233 -246
14
2006